$11.08
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating
Overview
52-week range
$7.12
$21
29% of range
Avg surprise (last 3)
-0.3%
Avg reaction (last 2)
-6.1%
50% positive
Latest IV / EM
172%
EM ±26.9% · $10 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.81 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-1.23 | $-1.26 | +2.4% | +11.5% | +3.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.90 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-1.44 | $-1.55 | +7.1% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.39 | $-1.26 | -10.3% | — | -15.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.90 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.83 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.27 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.05 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-4.24 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-36M | $-24M | — | $-24M | $-19M | $-20M | — | $-16M |
| Net income | $-35M | $-23M | — | $-23M | $-18M | $-17M | — | $-14M |
| EPS (diluted) | $-1.81 | $-1.23 | — | $-1.90 | $-1.44 | $-1.39 | — | $-1.15 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23M | $26M | $28M | $27M | $20M | $19M | $17M | $19M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $123M | $144M | $167M | $108M | $123M | $137M | $153M | $161M |
| Total assets | $127M | $144M | $168M | $110M | $125M | $140M | $156M | $164M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $25M | $18M | $21M | $17M | $14M | $13M | $13M | $14M |
| Total equity | $102M | $126M | $148M | $92M | $111M | $127M | $142M | $150M |